Overview GAIA’s digital therapeutic deprexis is now reimbursable in Switzerland for patients with mild to moderate depression and recurrent depressive disorders under the country’s man...
Overview A secondary analysis of a randomized controlled trial published in Behaviour Research and Therapy found that somnovia, GAIA’s digital insomnia therapy, primarily imp...
Overview The News DarioHealth announced the publication of a peer-reviewed study in JMIR Formative Research evaluating the real-world impact of its digital behavioral&n...
Overview Cerebral has acquired Inflow, a personalized ADHD digital therapeutic app, to strengthen its integrated mental healthcare platform and expand continuous support for patients w...
Overview GAIA reported positive results from a randomized controlled trial published in Psychological Medicine, demonstrating that attexis significantly reduced ADH...
Overview Lumos Labs has received FDA 510(k) clearance for LumosityRx, a prescription digital therapeutic (PDT) designed to improve attention in adults aged 22 to 55 with ADHD. Built o...
